Yokoyama, Masahiro
Kusano, Yoshiharu
Inoue, Norihito
Nishimura, Noriko
Mishima, Yuko
Nukada, Tomoyuki
Hatake, Kiyohiko
Terui, Yasuhito
Funding for this research was provided by:
Kyowa Kirin Co., Ltd.
Article History
Received: 29 August 2020
Accepted: 18 March 2021
First Online: 6 April 2021
Declarations
:
: The study was approved by the institutional Ethical Review Board. The analysis was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical Research on Individuals, the Law Concerning the Protection of Personal Information, and all other applicable laws and regulations concerning the handling of personal information.
: This was a retrospective observational study on data obtained from medical records. For this reason, the Ethical Review Board waived the need for obtaining informed consent from the patients.
: MY reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work. NN reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work. YM reports personal fees (for consultancy) from Chugai Pharmaceutical, outside the submitted work. TN reports personal fees (for employment) from Kyowa Kirin, during the conduct of the study. KH reports personal fees (for expert testimony) from Eisai and Otsuka Pharmaceutical, grants from AbbVie, Gilead Sciences, Celgene, Solasia Pharma, Pfizer, Bristol Myers Squibb, Janssen Pharmaceutical, Ono Pharmaceutical, and Chugai Pharmaceutical, personal fees (for speakers’ bureau and others) from Takeda Pharmaceutical and Taiho Pharmaceutical, personal fees (for speakers’ bureau) from Celgene, and personal fees (for others) from Kyowa Kirin, outside the submitted work. YT reports grants from Bristol Myers Squibb and personal fees (for speakers’ bureau) from Chugai Pharmaceutical, Novartis, Janssen Pharmaceutical, Celgene, Ono Pharmaceutical, Takeda Pharmaceutical, and MSD. YK and NI have nothing to disclose.